Skip to main content
SpringerLink
Log in

Proneurotensin als neuer „Biomarker“ für Brustkrebsrisiko?

  • Was Patienten fragen
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. „WELT Online“ vom 21.1.2014: Brustkrebs noch früher erkennen http://www.welt.de/print/die_welt/wissen/article124057623/Brustkrebs-noch-frueher-erkennen.html

  2. Melander O et al (2012) Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality. JAMA 308(14):1469-1475 http://jama.jamanetwork.com/article.aspx?articleid=1377922

Download references

Author information

Consortia

Springer Medizin-Verlag

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Springer Medizin-Verlag. Proneurotensin als neuer „Biomarker“ für Brustkrebsrisiko?. best practice onkologie 9, 52 (2014). https://doi.org/10.1007/s11654-014-0571-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0571-5

Search

Navigation